GSK given fright by broker talk of HIV rival

6 July 2017
gskbig-1

UK drugmaker GlaxoSmithKline (LSE: GSK) will be hoping for a stabilization in its share price on Thursday afternoon after a significant slide was started by a broker downgrading its stock recommendation.

Citigroup changed its buy rating to neutral and cut earnings forecasts by up to 9%, leading GSK’s share price to fall by 1.7% early in Wednesday’s trading, and on Thursday lunchtime its stock was again 1.3% down for the day at £16.04.

One of the reasons behind Citigroup’s less optimistic view on the drugmaker relates to its HIV business through its ViiV Healthcare unit, the fastest-growing part of its pharma division last year as sales rose by 37% to £3.56 billion ($4.59 billion). GSK's drug dolutegravir, which is used in the medicines Tivicay and Triumeq, has brought significant sales success.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical